Burnet Institute
  1. /
  2. Our work /
  3. Projects /
  4. PAVE PNG: partnership for vivax elimination
PAVE: Partnership for vivax elimination.

PAVE PNG: partnership for vivax elimination

Plasmodium vivax is a species of parasite that causes malaria. Nearly 40% of the world’s population remains at risk of P. vivax, which is now the most common cause of malaria outside of Sub-Saharan Africa and widely considered a major obstacle to achieving malaria elimination. Vivax malaria is a major cause of illness in Papua New Guinea. Together with PNG Institute of Medical Research, government partners and local communities, we’re partnering to eliminate vivax malaria in Papua New Guinea. 

We’re conducting work to develop a new strategy to treat and cure vivax malaria in Papua New Guinea.  

Tackling vivax malaria  

Children and rural communities in Papua New Guinea experience high rates of vivax malaria. When vivax malaria isn’t treated effectively, it can reoccur. This can lead to anaemia and make people more vulnerable to other health problems, such as pneumonia, diarrhoea and a higher risk of death.   If P. vivax radical cure can be implemented safely and effectively, then modelling predicts a significant impact on malaria incidence as well as community transmission, reducing the burden of malaria in the country. 

There have been recent advances in vivax malaria treatment. These include giving people with vivax malaria a higher dosage of the primaquine medication over a shorter timeframe. This drug may increase the risk of side effects for some patients, so we need to ensure a variety of safeguards. These safeguards include:  

  • additional tests before treatment  

  • check-ins after treatment.  

This project examines the feasibility of implementing new treatment plans for vivax malaria in Papua New Guinea, with the goal of informing national health policy. 

Women, men and children sitting outside together.
Medicines for Malaria Venture

Better malaria treatments can improve women and children's health.

What we’re doing

In partnership with PNG Institute of Medical Research, national and provincial government partners and local communities, we're conducting a study called SCOPE. SCOPE stands for Short COurse PrimaquinE for the radical cure of P. vivax. The SCOPE study investigates the safety and feasibility of a new treatment plan for vivax case management in Papua New Guinea and Indonesia.

The SCOPE study is a multicentre, implementation, before-and-after longitudinal study. It aims to determine the feasibility and cost-effectiveness of introducing a revised case management package for vivax malaria. Our aim is to deliver well-tolerated and effective ‘radical cure’ case management for people infected with vivax malaria. This radical cure will eliminate the parasite from a person’s body and completely cure them of malaria.  

This revised treatment package is being rolled out at:  

  • Mugil Health Centre in Madang province  

  • Baro clinic in West Sepik province  

  • Wirui clinic in East Sepik province  

  • Napapar Health Centre in East New Britain province.  

The revised case management package has been prioritised and endorsed by the Papua New Guinea National Department of Health. It includes:   

  • testing people prior to primaquine treatment to check their glucose-6-phosphate dehydrogenase (G6PD) activity by using a semi-quantitative point-of-care test. This determines the dosage of primaquine that they can receive 

  • prescription of an effective primaquine dose (6-7 mg/kg total dose) primaquine over 7 days,14 days or once a week for 8 weeks (informed by G6PD activity), to all eligible patients with P. vivax malaria  

  • patient education and counselling prior to treatment and supervision of the first dose of primaquine at the healthcare clinic 

  • community-based clinical review at day 3 of primaquine treatment, to encourage treatment adherence and detect side effects  

  • improved malaria surveillance (monitoring)  

  • checking for side effects (pharmacovigilance).

A G6PD point of care testing device.
Medicines for Malaria Venture (MMV)

A G6PD point of care testing device.

About primaquine treatment and G6PD deficiency

The 2015 WHO antimalarial treatment guidelines recommend low or standard dose primaquine (0.25mg/kg/day for 14 days), but higher doses can be used in areas with a high risk of relapse (0.5mg/kg/day for 14 days). 

The World Health Organization recommends that all patients are tested for G6PD deficiency prior to treatment. G6PD (glucose-6-phosphate-dehydrogenase) deficiency is a health condition that can lead to adverse side effects from primaquine medication. It can lead to haemolysis (breakdown of red blood cells). In people with G6PD deficiency, a course of 0.75mg/kg/week for 8 weeks is recommended but there is limited evidence for this regimen.  

Higher dose regimens may be more effective in Papua New Guinea and Indonesia, but routine G6PD testing is not yet widely available in either country. There can also be barriers to following through with treatment. This study aims to address this by including G6PD testing and follow ups as part of the treatment plan. 

A health worker from Papua New Guinea Institute of Medical Research points to an illustration of primaquine.
Medicines for Malaria Venture (MMV)

PNGIMR community health worker Odillia Arib provides education on vivax malaria and primaquine to a patient in Madang.

Who’s involved  

We're doing this through PAVE PNG, a consortium that includes Burnet Institute, the Papua New Guinea Institute of Medical Research and Papua New Guinea National Department of Health. The consortium is funded by Unitaid through Medicines for Malaria Venture (MMV). It's part of a group of similar public health programs being run across Brazil, Peru, Indonesia, Vietnam and Ethiopia.

The SCOPE study is a partnership with the Papua New Guinea Institute of Medical Research and National Malaria Control Program. The study includes 4 local health clinics across 4 provinces, with close collaboration with Papua New Guinean Provincial Health Authorities. We also collaborate with Menzies School of Health Research, PATH and the University of Melbourne. 

Learn more about PAVE

An illustration of the world.

Watch the video to learn more about PAVE PNG.

Hello, my name is Dr Moses Laman. I am the deputy director of the Papua New Guinea Institute of Medical Research. I have close to 20 years of experience in malaria research and within Papua New Guinea, vivax malaria is a big problem. The parasites hide in the liver and it is not easy to treat. Because of this, we are working on a treatment, that will effectively treat and cure vivax malaria. And we are working in partnership with the National Department of Health, Provincial Health Authorities, Burnet Institute and 4 clinics within Papua New Guinea, to find a better way to treat and cure vivax malaria. In this video, you will learn some things about vivax malaria and the treatment for it. 

What is vivax malaria? Sik vivax malaria em wanem?

Plasmodium vivax is a type of malaria that is common in Papua New Guinea. Similar to other kinds of malaria, the parasite that causes vivax malaria is transmitted by female anopheles mosquitoes. 

After the mosquito injects the malaria parasites into the bloodstream, the parasites multiply in the blood and cause illness.

Mala-1 is the medicine that treats the malaria parasites that are in the blood. However vivax malaria has a stage that can hide or sleep in the liver, called hypnozoites, for weeks, months and even years. This hidden liver stage of vivax malaria can come out into the blood every now and then, causing repeated infection and illness. When picked up by a mosquito, it passes onto another person causing them infection and illness. 

These repeated episodes of infection and illness can cause both acute and chronic health problems.

Primaquine is the medicine that removes the hidden malaria parasites from the liver. 

Primaquine / Primakwin

Primaquine is an anti-malarial medicine that is approved by the PNG government to treat and remove the hidden liver stage parasites of vivax malaria in Papua New Guinea. Mala-1 treats the blood stage of the parasite but not the liver stage. Meaning even though you complete Mala-1 and feel better, only the blood stage of the parasite has been cleared, the liver stage will remain for months and then emerge into the bloodstream and reinfect you. 

This is why it’s important to complete primaquine antimalarial treatment to successfully clear all the parasites in the liver.

Primaquine can cause severe side effects in some people. So the dose of primaquine needs to be determined by a test that the health worker will do. As a result, Papua New Guinea Institute of Medical Research is conducting a study to introduce this new test to determine the optimal dose of primaquine to clear all the stages of vivax malaria. 

Possible side effects of primaquine to be aware of / Makmak we i ken kamap taim sik manmeri i kisim primakwin

These are the signs/symptoms to be aware of when taking primaquine because they require immediate clinical care.

Displa em ol mak we sikman o wasman blong sikman i mas lukuluk long em. Taim displa ol mak i stat long kamap long dikman, em mas toksave kwik taim long ol wokman blong haus sik. 
- Dark urine - red or the colour of Coca Cola / Kala belong pisps i senis em l ken Luk orem red o kala blong koko kola 
- Nausea and/or vomiting / pill trait bel tanim
- Yellow of the skin or the whites of the eyes / kala blong skin I Luk yelo/waitpla pat blong ai em go yelo
- Breathlessness or shortness of breath / Hat long pulim win/Sotwin
– Dizziness / Ai raun 
– Rapid heart rate / Hatbit blong sikman i  hariap hariap tumas
– Fever / Skin hot 
– Pale skin or unhealthy appearance / kala blong skin blong sikman i kamap lait liklik o em i luk sik
– Fatigue / Filim silip planti

If you have these signs/symptoms you should seek care from your nearest clinic or hospital. 

Sapos sikman i gat displa ol makmak, em mas go lukim ol wokman long haus sik we stap klostu long em.

Primaquien can also cause gastrointestinal upset, especially if you do not take it with food.

Primakwin i ken kamapim bel pen na bel tanim anim. Displa em bai kamap sapos yu no kaikai gut pastaim long yu kisim marasin. 

Taking primaquine as directed by your health worker / Kisim primakwin osem hau ol wokman bilong haus sik i tokim yu

For primaquine, it is the total dose that you take that determines whether all the parasites in the liver are cleared and the treatment is effective. This totla dose needs to be split over multiple days in order for the treatment to be safe. It is extremely important that the total amount of primaquine presscribed to you is taken according to the health workers instructions. It is important to not give your primaquine tablets to other members of thecommunity as it will impact its effetiveness on curing your vivax malaria infection and it will not be good for the person who receives the primaquine. To minimise the risk of gastrointestinal side effects when taking primaquine, take your medication with food. 

I hope you have learned something from this video and remember, if you are sick, you must get treatment from the nearest clinic or hospital. Always remember to sleep under a mosquito net, and lastly, I thank you for watching. I thank all the communities that are supporting us to do research to help eliminate malaria in Papua New Guinea. Thank you.

Learn more about plasmodium vivax

Scientist looks into a microscope.

Watch the video to learn more about P. vivax.

P. vivax malaria poses a persistent challenge to our shared malaria elimination goals. Unless fully treated, the parasite can hide in a person's liver, causing recurring illness, which can lead to severe anemia and even death. 
Children are 4 times as likely as adults to be infected. 

The Partnership for Vivax Elimination (PAVE) seeks to support countries in accelerating elimination of P. vivax malaria. PAVE coordinates with malaria programs to develop tailored approaches to support the introduction and optimal use of effective diagnostics and treatments. This will lead to more people being fully treated. 
Tackling P. vivax is key to eliminating malaria. Together, we can beat it. 

Project outputs

More information

Partners

Funding partners

The SCOPE study is part of a Unitaid-funded PAVE consortium of partners.

Partner logo

Collaborators

  • Papua New Guinea Institute of Medical Research
  • PNG National Department of Health
  • PNG National Malaria Control Program
  • PNG Pharmaceutical Services and Standards Branch
  • Madang Provincial Health Authority
  • East New Britain Provincial Health Authority
  • East Sepik Provincial Health Authority
  • West Sepik Provincial Health Authority  
  • The University of Melbourne
  • Menzies School of Public Health
  • Medicine for Malaria Venture (MMV)  
  • PATH
  • Unitaid

Project contacts

Main contact

Professor Leanne Robinson

Professor Leanne Robinson

Project Director
View profile
Paul Daly

Paul Daly

Senior Project Manager
View profile

Project team

Professor Leanne Robinson

Professor Leanne Robinson

PAVE Project Director
View profile
Paul Daly

Paul Daly

Senior Research Officer, Project Manager
View profile
Evelien Rosens

Evelien Rosens

Senior Research Officer
View profile
Annie Dori

Annie Dori

Partnerships Manager
View profile
Rachael Farquhar

Rachael Farquhar

Senior Research Officer
View profile
Marina Bishop

Marina Bishop

Senior Project Officer
View profile
Dr Mary Malai

Dr Mary Malai

Country SCOPE Study Lead
Papua New Guinea Institute of Medical Research
Moses Laman

Moses Laman

PAVE PNG Principal Investigator
Papua New Guinea Institute of Medical Research
View profile
Dr Maria Ome-Kaius

Dr Maria Ome-Kaius

PAVE PNG Co-Principal Investigator
Papua New Guinea Institute of Medical Research
Professor Ric Price

Professor Ric Price

PAVE Project Director (Indonesia)
Menzies School of Health Research, Charles Darwin University
View profile
Dr Jeanne Rini Poespoprodjo

Dr Jeanne Rini Poespoprodjo

PAVE Indonesia Principal Investigator
Universitas Gadjah Mada; Yayasan Pengembangan Kesehatan dan Masyarakat Papua
Professor Ayodhia Pitaloka   Pasaribu

Professor Ayodhia Pitaloka Pasaribu

PAVE Indonesia Principal Investigator
Universitas Sumatera Utara
Professor Julie Simpson

Professor Julie Simpson

SCOPE Head Statistician
University of Melbourne
View profile
On this page